Skip to main content

Advertisement

SpringerLink
Log in

Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: a clinical practice observational study of patients who discontinued treatment

  • Short Communication
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

TNF-alpha-blocking agents (anti-TNF) used in juvenile idiopathic arthritis (JIA) are well established; however, time to withdraw is unclear. Neither prolonged nor tapering treatment seems to influence risk of relapse. Our aim was to assess relapse percentage after anti-TNF withdrawal of our non-systemic JIA patients after reaching clinical remission. A retrospective review of our non-systemic JIA patients in whom anti-TNF had been withdrawn due to inactive disease was achieved, between December 2000 and November 2011. We analyzed percentages of relapse according to JIA categories and antinuclear antibodies (ANA) positivity. n = 18 patients were included. Eighty-two percentage of patients relapsed after treatment withdrawal, and mean time to relapse was 3.04 months (SD 2.03). The percentage of relapse after anti-TNF discontinuation in the main JIA category was 88 % of negative rheumatoid factor polyarticular JIA and 80 % of persistent oligoarticular JIA. We did not find significant statistical differences according to ANA positivity (9 of 14 were ANA positive), and mean time to relapse (days) was 85.0 (SD 69.4) for ANA-positive versus 102.4 (SD 47.7) for ANA-negative patients (p = NS). Relapse percentage following anti-TNF discontinuation was high (82 %) and occurred within the first 3 months after it. No relationship regarding JIA subtype and ANA positivity was found.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Beukelman T, Patkar NM, Saag KG et al (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthr Care Res 63(4):465–482

    Article  Google Scholar 

  2. Prince FHM, Twilt M, Simon SCM et al (2009) When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 68(7):1228–1229

    Article  CAS  PubMed  Google Scholar 

  3. Pratsidou-Gertsi P, Trachana M, Pardalos G et al (2010) A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission. Clin Exp Rheumatol 28(6):919–922

    CAS  PubMed  Google Scholar 

  4. Remesal A, De Inocencio J, Merino R et al (2010) Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. J Rheumatol 37(9):1970–1971

    Article  PubMed  Google Scholar 

  5. Baszis K, Garbutt J, Toib D et al (2011) Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthr Rheum 63(10):3163–3168

    Article  Google Scholar 

  6. Postepski J, Kobusinska K, Olesinska E et al (2012) Clinical remission in juvenile idiopathic arthritis after termination of etanercept. Rheumatol Int 21 Jul [Epub ahead of print]

  7. Petty RE, Southwood TR, Manners P et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392

    PubMed  Google Scholar 

  8. Wallace CA, Ruperto N, Giannini E (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31(11):2290–2294

    PubMed  Google Scholar 

  9. Ravelli A, Varnier GC, Oliveira S et al (2011) Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthr Rheum 63(1):267–275

    Article  Google Scholar 

  10. Ravelli A, Felici E, Magni-Manzoni S (2005) Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthr Rheum 52(3):826–832

    Article  Google Scholar 

  11. Felici E, Novarini C, Magni-Manzoni S et al (2005) Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. J Rheumatol 32(9):1805–1810

    PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they do not have any conflict of interest.

Author information

Authors and Affiliations

  1. Pediatric Rheumatology Unit, Hospital Sant Joan de Déu-Universitat Barcelona, Passeig Sant Joan 2, 08950, Esplugues de Llobregat, Barcelona, (Catalunya), Spain

    Estíbaliz Iglesias, Vicenç Torrente-Segarra, Rosa Bou, Silvia Ricart, María Isabel González, Judith Sánchez, Joan Calzada & Jordi Antón

Authors
  1. Estíbaliz Iglesias
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vicenç Torrente-Segarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rosa Bou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia Ricart
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. María Isabel González
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Judith Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joan Calzada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jordi Antón
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vicenç Torrente-Segarra.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 325 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iglesias, E., Torrente-Segarra, V., Bou, R. et al. Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: a clinical practice observational study of patients who discontinued treatment. Rheumatol Int 34, 1053–1057 (2014). https://doi.org/10.1007/s00296-013-2884-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-013-2884-z

Keywords

Search

Navigation